Treatment of Refractory/Resistant CMV in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management

Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV.

Topics include:

• Considerations for CMV management in HCT recipients
• New definitions of refractory and resistant CMV
• Risk factors for refractory and resistant CMV infections
• Identifying drug-resistant CMV
• Treatment options for refractory/resistant CMV

To view the full educational program and download the accompanying slides, visit our website:
https://bit.ly/4lfrDTT

Presenters:

Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID
Professor and Chair
G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
President, The International Immunocompromised Host Society (ICHS)
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, Texas

Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.